Cuprina Holdings (Cayman) Limited closed its public offering by fully exercising the underwriter's over-allotment option on September 29, 2026. The company issued and sold an additional 648,373 Class A ordinary shares at a price of $1.15 per share, generating approximately $745,629 in gross proceeds. This brings the aggregate gross proceeds from the offering to approximately $5,716,491, prior to deducting underwriting discounts and expenses. The company also issued warrants to purchase 25,935 shares to the representative of the underwriters at an exercise price of $1.265 per share. Cuprina Holdings is a biomedical and biotechnology company developing products for chronic wounds, infertility, medical waste recycling, and cosmeceuticals.
